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CD9, a member of the tetraspanin family of proteins, is involved in a variety of cellular interactions with many other proteins and
molecules. Although CD9 has been implicated in cell fusion, migration and cancer progression, the detailed function of this protein is
not completely understood and likely depends on interactions with different protein partners, which are not yet all known. Using co-
immunoprecipitation and mass-spectrometric protein sequencing, we have identified in prostate cancer cells, a novel CD9 partner,
the 75-kDa protein HSPA9B, also known as mortalin. We further show that introduction and overexpression of wild-type CD9 into
human PC-3 prostate cancer cells induces mitotic catastrophe. We also demonstrate, by immunocolocalisation studies, the
interaction of CD9 and mortalin in PC-3 cells undergoing mitotic catastrophe. Our results not only identified mortalin as a new CD9
partner, but also clarify the mechanisms by which CD9 may control prostate cancer progression.
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The cluster-of-differentiation antigen 9 (CD9) protein belongs to
the family of tetraspanin (also called transmembrane 4 superfamily
or TM4SF) whose members have been implicated in cell motility
and cell–cell interactions. In humans, the tetraspanin family is
composed of at least 32 members (Boucheix et al, 2004). Many of
these proteins (including CD9) are broadly expressed and form
complexes with different partners, including other tetraspanins
(Maecker et al, 1997), integrins (Berditchevski and Odintsova,
1999) and lineage-specific proteins (Hemler, 2001). Through these
interactions and the formation of homodimers (Kovalenko et al,
2004), tetraspanins serve as building blocks in multicomponent
protein complexes (Boucheix et al, 2004) and are considered to be
‘molecular facilitators’ (Maecker et al, 1997).
Cluster-of-differentiation antigen 9 (also called MRP1) was
identified as the antigen binding to the mAb M31-15, an antigen
found to inhibit the motility of various cancer cell lines (Miyake
et al, 1991). Elevated CD9 expression is considered a favourable
prognosticator in head and neck squamous cell carcinoma (Erovic
et al, 2003). Cluster-of-differentiation antigen 9 is also expressed at
higher levels in primary tumours as compared to metastatic
human colon carcinoma cells (Cajot et al, 1997). Decreased CD9
expression has been associated with poor prognosis in breast
(Miyake et al, 1996), non-small-cell lung cancer (Higashiyama
et al, 1998), non-Hodgkin’s lymphoma (Yau et al, 1998), and in
oesophageal squamous cell carcinoma (Uchida et al, 1999).
Exogenous expression of CD9 suppressed motility of mouse
melanoma cells, and reduced their metastatic potential (Ikeyama
et al, 1993). Our recent studies have shown that CD9 expression is
also significantly reduced and even lost during prostate cancer
progression (Wang et al, 2007). In contrast, in gastric cancers, CD9
facilitates cell proliferation through enhancement of the mitogenic
activity of HB–EGF and consequently influences cancerous cell
proliferation or metastasis generation (Hori et al, 2004). Moreover,
exogenous CD9 expression does not significantly affect the growth
and the invasive properties of a highly metastatic prostate cancer
cell line (Zvieriev et al, 2005).
The current work was undertaken to understand the phenotypic
differences observed following expression of CD9 in prostate
tumour cell lines having increased metastatic potential. We show
that overexpression of CD9 in human PC-3 prostate cancer cells is
sufficient to induce mitotic catastrophe, which is also known as
mitotic cell death. In contrast, overexpression of CD9 in PC-3
variants, obtained from serial in vivo selection using orthotopic
implantation in nude mice and having increased metastatic
potential (Pettaway et al, 1996), did not induce mitotic catastrophe
(Zvieriev et al, 2005). Since CD9 is known to interact with other
tetraspanins as well as other proteins involved in different cellular
functions, the differences in phenotypic changes brought by CD9
expression in various types and aggressiveness of cancer cells are
likely to depend on the presence or absence of different CD9
partners.
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sIn order to characterise such partners in prostate cancer cells, we
used mass-spectrometric analysis to identify proteins that co-
immunoprecipitated with CD9. One of these proteins was the
HSPA9B protein, a member of the heat-shock protein 70 (hsp70)
family also known as mortalin. Mortalin, a putative oncogene
product, has been implicated in many biological processes such as
control of cell proliferation (Kaul et al, 2000b), differentiation (Xu
et al, 1999) and tumorigenesis (Takano et al, 1997). Although
mortalin is ubiquitously expressed, differential cellular localisation
of mortalin in human cancer cells has been associated with cell
senescence (Wadhwa et al, 1995). Indeed while in normal cells,
mortalin is evenly distributed throughout the whole cytoplasm, in
cancer cells it varies from fibrous or granular perinuclear
localisation to a pan-cytoplasmic gradient. Here, we show that
mortalin is not only associated with CD9, but also immunolocalised
with CD9 when cells undergo CD9-induced mitotic catastrophe.
MATERIALS AND METHODS
Cell culture and transfections
The human PC-3 prostate cancer cell line, originally established
from a bone metastasis of a grade IV prostate cancer (Kaighn et al,
1979), was obtained from the American Type Culture Collection
(Manassas, VA, USA). The PC-3M cell line was derived from a liver
metastasis of PC-3 cells following intraspleenic injection of these
cells in nude mice (Pettaway et al, 1996). Sequential orthotopic
injections of PC-3M cells into the prostate of nude mice generated
a very aggressive prostate-growing cell line (the prostate-selective
PC-3M-Pro4) and a highly migrating lymph node metastatic cell
line (the lymph node-selective PC-3M-LN4) (Pettaway et al, 1996).
PC-3M, PC-3M-Pro4 and PC-3M-LN4 were kindly provided by IJ
Fidler (The University of Texas MD Anderson Cancer Center,
Houston, TX, USA). The DU 145 cell line, originally derived from a
prostate cancer brain metastasis (Stone et al, 1978), was obtained
from the American Type Culture Collection. Cells were cultured in
RPMI-1640 medium (Canadian Life Technologies, Burlington, ON,
Canada) supplemented with 10% fetal bovine serum (Canadian
Life Technologies). All cell lines were grown in the absence of
antibiotics in a humidified incubator at 371C and 5% CO2 and were
free of mycoplasma as determined by Hoechst 33342 staining
(Chen, 1977).
Generation of CD9 expression vector was described else-
where (Zvieriev et al, 2005). PC-3, PC-3M, PC-3M-Pro4, PC-3M-
LN4 and DU 145 cells were stably transfected with pcDNA3.1/
Myc-HisA-CD9 wild-type construct using SuperFectt transfection
reagent (Qiagen, Mississauga, ON, Canada) following the manu-
facturer’s instructions. Stable clones were selected in media
containing 1000mgml
 1 of G418 (Canadian Life Technolo-
gies) and further maintained in the presence of 400mgml
 1 of
G418. PC-3CD9 overexpressing clones were also obtained from a
pool population of CD9-transfected PC-3 cells. Diluted single-cell
suspensions of CD9-transfected PC-3 cells were seeded in Petri
dishes (30–50 cells per dish). After 21 days in culture, individual
CD9-transfected clones containing 200–500 cells were isolated.
Immunoprecipitation and immunoblotting
Anti-CD9 (MM2/57) and anti-actin (CBL171) mAbs were obtained
from Chemicon International (Temecula, CA, USA), anti-mortalin
mAb (MA3-028) was purchased from eBiosciences (San-Diego, CA,
USA), and HRP-coupled goat anti-mouse secondary antibody (no.
31430) was from Pierce Biotechnology (Rockford, IL, USA). Non-
immune mouse IgG was purchased from Sigma-Aldrich Canada
Ltd (Oakville, ON, Canada).
For immunoprecipitation and immunoblotting studies, cells
were grown in 100mm Petri dishes and harvested in lysis buffer
containing 1% Brij
r 97, 25mM HEPES, pH 7.5, 150mM NaCl, 5mM
MgCl2,2m M PMSF, 10mgml
 1 aprotinin and 10mgml
 1 leupeptin.
For co-immunoprecipitation experiments, protein extracts (1mg)
were precleared and incubated overnight with a specific CD9 mAb
(2mg of MM2/57) and protein Sepharose G beads (1:1 slurry, GE
Healthcare, Baie d’Urfe, QC, Canada). Immunocomplexes were
collected by boiling in Laemmli buffer, loaded onto SDS-PAGE and
run under non-reducing conditions. Silver staining was used to
reveal proteins obtained from CD9 immunocomplexes. Bands were
excised, digested with proteases and sequenced using matrix-
assisted laser desorption/ionisation time-of-flight mass spectro-
metry (MALDI-TOF MS at the proteomics platform of McGill
University and Genome Quebec Innovation Centre, Montreal, QC,
Canada). For immunoblotting, following SDS-PAGE (run under
reducing condition for mortalin detection and non-reducing for
CD9 detection), the proteins (50mg) were transferred to Trans-Blot
Transfer Medium Membrane (Bio-Rad Laboratories, Hercules, CA,
USA) and blocked in 5% non-fat dry milk. Protein bands were
detected with mortalin primary mAb (1:500 dilution), or CD9
primary mAb (1:500 dilution). Signal was amplified with HRP-
coupled goat anti-mouse secondary antibody (1:2000 dilution)
and detected with a chemiluminescent kit (Amersham, Oakville,
ON, Canada). Actin detection (MAB1501R; 1:2000 dilution) was
performed to confirm equal protein sample loading.
Immunofluorescence and colocalisation studies
Cells seeded onto glass coverslips in six wells were fixed in 3.7%
paraformaldehyde following incubation in 50mM of ammonium
chloride, and permeabilised in 0.2% (vv
 1) Triton X-100. Signal
detection was obtained by a mixture of primary antibodies (1:50
dilution for mortalin antibody; 1:300 for CD9 antibody). In co-
immunostaining experiments, goat anti-mouse conjugated Alexa
555 and goat anti-mouse conjugated Alexa 488 (Invitrogen,
Burlington, ON, Canada) were used as fluorochromes. The
coverslips were inverted on a glass slide and treated with Immu-
Mount mounting medium (ThermoShandon, Pittsburgh, PA,
USA).
Cells were imaged using a Zeiss LSM 5 Pascal confocal
microscope (Carl Zeiss International, Toronto, ON, Canada) with
a  100/1.3 objective and an argon laser (488nm). Images were
processed using the Axiovision (Carl Zeiss International) and
Adobe Photoshop (Adobe Systems, Mountain View, CA, USA)
programs.
Immunocytochemistry
A total of 2–4 10
4 cells were seeded onto coverslips in a 12-well
plate and incubated overnight at 371C. The next day, adherent cells
were fixed with 3% of prechilled formaldehyde and ice-cold
methanol. A section of benign prostatic hyperplasia (BPH) from
transurethral resections of the prostate served as an external
positive control for each immunocytochemistry staining. Before
staining, endogenous peroxidase was removed by 3% solution of
hydrogen peroxide (H2O2; Fisher Scientific, Nepean, ON, Canada)
in 50% methanol (Fisher Scientific). The Histostaint-SP kit
(Zymed, South San Francisco, CA, USA) was used to detect and
amplify the signal originating from the binding of antibody to CD9
antigen. Cluster-of-differentiation antigen 9 protein expression
was detected with monoclonal mouse anti-human CD9 antibody
(NCL-CD9; 1/300 dilution; Novocastra Laboratories, Burlingame,
CA, USA). The staining signal was revealed upon incubation with
DAB substrate, prepared by dissolving Fast DAB tablets (Sigma-
Aldrich Canada Ltd) in ddH2O. Cells were counterstained with
haematoxylin and dehydrated in increasing graded ethanol and
toluene. The coverslips were inverted on glass slides and sealed
with Cytoseal 60 mounting solution (Richard-Allan, Kalamazoo,
MI, USA).
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Wild-type CD9 overexpression induces mitotic catastrophe
in PC-3 prostate cancer cells
We had already demonstrated that as compared to BPH, the CD9
protein is expressed at lower level in human prostate cancer cell
lines (data not shown). Therefore, to characterise further the role
played by CD9 in prostate cancer, we stably transfected and
overexpressed wild-type CD9 in PC-3 cells and its derivatives (all
originally obtained upon injection in nude mice), namely PC-3M
(a liver metastasis obtained upon PC-3 intraspleenic injection),
PC-3M-Pro4 (a highly aggressive cancer cell line selected upon
sequential orthotopic PC-3M injections) and PC-3M-LN4 (a very
aggressive lymph node metastatic cell line selected upon sequential
orthotopic PC-3M injection). While cultured PC-3 cells appear as
small and rounded (Figure 1A), in contrast, CD9-transfected PC-3
cells underwent drastic morphological changes (Figure 1B and D).
Characteristic appearances of CD9-transfected cells included an
enlarged cell surface, prominent cellular projections (indicated by
an arrow in Figure 1B), and multiple nuclei (Figure 1B and as
shown by an arrowhead in Figure 1D). Compared to parental PC-3
cells (Figure 1A), the cell surface of some CD9-transfected cells
increased by as much as 10-fold (Figure 1B and D). Many
intracytoplasmic vacuoles were seen in those enlarged cells
(Figure 1B). Cluster-of-differentiation antigen 9-overexpressing
PC-3 cells also had a limited lifetime and usually reached less than
10% of cell confluence. Such morphological changes were also seen
in some CD9-transfected PC-3M cells (Figure 1C). As these
phenotypic changes became more severe, fewer cells appeared to
be in mitosis. Eventually, all cells exhibited pronounced pheno-
typic changes and overall less than 10 cells remained in the flask.
Such characteristics are hallmarks of a particular type of cell death
called mitotic catastrophe, which Roninson et al (2001) defined as
a type of cell death resulting from abnormal mitosis ending in the
formation of large cells with multiple micronuclei and decon-
densed chromatin. These morphological changes also contrast with
the shrunken cytoplasm and the condensed nuclei seen when cells
undergo apoptosis (Roninson et al, 2001). We have detected a low
percentage of such apoptotic cells in some CD9-transfected cells
that either underwent or not mitotic catastrophe. Although mitotic
catastrophe is sometimes followed by apoptosis (Jordan et al,
1996), it is not required for the lethal effect of mitotic catastrophe.
It thus seems that CD9-induced mitotic catastrophe is not followed
by apoptosis, a result consistent with the p53-null status of PC-3
cells (Isaacs et al, 1991), and with the reported apoptosis-reluctant
status of PC-3M (a derivative of PC-3) cells (Demidenko and
Blagosklonny, 2004).
We followed the fate of 61 CD-9-transfected PC-3 clones and
found that 33% underwent mitotic catastrophe (Table 1). In
contrast, CD9-transfected cells from the remaining two-thirds of
PC-3 clones, 91% of PC-3M clones and 100% of PC-3M-Pro4, PC-
3M-LN4 and DU 145 clones did not show any sign of mitotic
catastrophe (Table 1) and could be kept more than 7 months in
culture. We also obtained 57 ‘mock-transfected’ clones (containing
pcDNA3.1A vector). Among these clones, 25 were derived from
PC-3 cells, and none exhibited mitotic catastrophe (Table 1).
Although individual CD9-transfected PC-3 clones were isolated
and expanded, many more were obtained and kept as pools. Since
CD9-transfected clones eventually died, we subcloned the pooled
population (at passage 2) to generate more CD9-transfected PC-3
clones. Fifty-three clones were picked and seeded into two T25
flasks (day 0). This allowed us to better define the time course of
the induction of mitotic catastrophe in these cells (described in
Figure 2). Clones were observed under the microscope and results
were recorded on a weekly basis. Growth differences were observed
by day 11. Out of the 53 clones picked, only 24 clones grew well
and were cultured for many passages. Six clones from this series
were maintained for more than 3 months. On the other hand, 7 of
the 29 clones that did not originally grow started to grow by day
22. At the same time, moderate morphological changes, such as
presence of enlarged cells, became evident in 22 of the 29 non-
growing clones; these cells eventually experienced mitotic cata-
strophe. By day 39, nine clones were no longer viable. In the 13
remaining clones, isolated colonies started to grow by days 43–46
and viable cultures were obtained from six of them. The remaining
seven clones eventually died at day 53 (three clones), day 74 and
day 119 (two clones each). Overall, CD9 was able to induce mitotic
catastrophe in 16 of 53 clones (30%) after approximately 56 days of
culture. The percentage of CD9-transfected cells undergoing
mitotic catastrophe in this subset of clones was very similar to
the one obtained in the original selection, where 20 of 61 PC-3 CD9
clones (33%) died after 48 days in culture (Table 1). Indeed, there
is no statistical difference between both sets of CD9-transfected
clones undergoing mitotic catastrophe (P¼0.84 by Fisher’s exact
Figure 1 Cluster-of-differentiation antigen 9 (CD9) overexpression
induces mitotic catastrophe in PC-3 cells. Morphology of PC-3 (untrans-
fected) and CD9-transfected PC-3 cells, photographed under phase-
contrast microscope. (A) PC-3 (untransfected) cell morphology showing
the presence of rounded, dividing cells at passage 20. (B) Cells with
significant morphological changes are shown here for the PC-3CD9-69
clone at passage 1. An arrow indicates a cell with characteristic spindle-like
cellular projections. (C) A mixture of prominent enlarged cells and small
spindle-shaped cells of PC-3MCD9-16 clone at passage 1. Immunocyto-
chemical staining revealed that all enlarged cells highly express CD9
protein, whereas most small, spindle-shaped cells expressed a very low
amount (if any) of CD9. These CD9-negative cells will gradually become
the dominant growing population. (D) Picture of an exaggerated enlarged
cell with CD9 staining from PC-3CD9-18 at passage 0 (arrowhead). Break
down of cytoskeleton is visible in the cell just below it. Most cells have an
intense and diffuse CD9-staining pattern, occasionally with punctuate
distribution. (Original magnification: A–D,  100)
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clones undergoing mitotic catastrophe between CD9- and vector-
transfected PC-3 cells is highly significant (P¼0.0017).
Cluster-of-differentiation antigen 9 immunocytological staining
was performed on 50% (57 of 114) CD9-transfected PC-3 clones.
Since most dying clones could not be divided to allow
immunocytochemistry staining, we were only able to stain 5 out
of 36 clones (from both sets of clones). Immunocytochemical
analysis showed that all five dying clones were CD9-positive. In
contrast, only 14 (27%) of the 52 growing clones were CD9-
positive. Thus, the majority (73%) of these clones had lost
exogenous CD9 expression. Moreover, most growing CD9-positive
clones experienced a gradual reduction of CD9 expression, as seen
by lower CD9-staining intensity and decreasing population of
CD9-positive cells in culture. The difference in CD9 expression
between dying and growing clones was highly significant using
either w
2 test (P¼0.0009) or Fisher’s exact test (P¼0.003). This
lack of exogenous CD9 expression in surviving CD9-transfected
clones was confirmed by immunoblotting (Figure 3). These results
show that when CD9-transfected PC-3 cells are kept in culture,
exogenous CD9 protein expression was silenced, allowing the
growth of these cells.
Identification of CD9-associated protein
Like other tetraspanins, CD9 interacts with many partners, such as
integrins and other tetraspanins (Hemler, 2001; Charrin et al,
2003). Indeed, more than 30 CD9 partners have recently been
Table 1 Outcome of wild-type CD9 overexpression in human prostate
cancer cell lines
Prostate cancer
cell lines
a
No. of clones
analysed
No. (percentage) of clones
undergoing mitotic catastrophe
DU 145 29 0 (0%)
PC-3 61 20 (33%)
PC-3
b
(pcDNA3.1A)
25 0 (0%)
PC-3M 22 2 (9%)
PC-3M-Pro4 63 0 (0%)
PC-3M-LN4 39 0 (0%)
aDU 145 is a prostate patient-derived brain metastasis; PC-3 is a prostate patient-
derived bone metastasis. PC-3M, PC-3M-Pro4 and PC-3M-LN4 were obtained upon
injection of cells in nude mice. PC-3M was derived from a liver metastasis of PC-3
intraspleenic injection; both PC-3M-Pro4 (growing very aggressively in the prostate)
and PC-3M-LN4 (rapidly forming lymph node metastasis) were obtained upon
sequential orthotopic injections of PC-3M cells.
bPC-3 (pcDNA3.1A) represents
stable PC-3 clones analysed upon transfection with the empty vector (pcDNA3.1A).
Day 11 Day 22
Day 22 Day 0
Day 11
Day 22
In total
16 out of 53 clones (30%) died
by mitotic catastrophe
(in average by day 56)
Day 39
Day 39
Day 39
Day 39
Day 74
Day 119
Day 119
Day 119
Day 119
Day 53
24 clones
are growing
29 clones
do not grow
53 clones
are picked
6 clones
are growing
7 clones
are growing
9 clones died
by mitotic catastrophe
22 clones start displaying
morphological changes
3 clones died
by mitotic catastrophe
2 clones died
by mitotic catastrophe
2 clones died
by mitotic catastrophe
7 clones
start to grow
6 clones
are growing
7 clones
are growing
6 clones
eventually grew
13 clones contain
few dividing cells
24 clones grew to confluence
6 clones are kept in culture
Figure 2 Growth characteristics and induction of mitotic catastrophe in cluster-of-differentiation antigen 9 (CD9)-transfected PC-3 clones. Fifty-three
CD9-transfected PC-3 clones were monitored weekly. Six of the 24 clones showing strong growth capabilities were cultured for 119 days. Sixteen clones
that had a limited lifetime were followed until mitotic catastrophe. In summary, 16 of 53 clones (30%) experienced mitotic catastrophe on average after 56
days of cell culture.
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Figure 3 Lack of exogenous cluster-of-differentiation antigen 9 (CD9)
expression in surviving PC-3-transfected cells. Detection of CD9 in
prostate cancer cells by Western immunoblot using CD9 monoclonal
antibody. Protein extracts (55mg) from six surviving CD9-transfected PC-3
clones, from PC-3 and from PC-3M-LN4 cells are compared to different
amount of protein extracts (12–72mg) from PC-3M-LN4CD9-40 cells
expressing exogenous CD9.
CD9 and mortalin during mitotic catastrophe
V Zvereff et al
944
British Journal of Cancer (2007) 97(7), 941–948 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sidentified in colon cancer cells; CD9 partners even differ between
cell lines established from the primary tumour and the metastases
obtained from a unique patient (Le Naour et al, 2006). We
hypothesised that differential expression or distribution of such
partners could be responsible for the striking differences observed
following CD9 overexpression in the different human prostate
cancer cell lines (Table 1). Immunoprecipitation was thus used in
an attempt to identify such partners. For these studies, PC-3 and
PC-3M-LN4 cells were used since they respond differently to CD9
overexpression (Table 1). Cluster-of-differentiation antigen 9
immunocomplexes obtained from Brij 97 lysates of PC-3 and
PC-3M-LN4 cells were fractionated by SDS-PAGE. Silver staining
of the gel revealed a 75-kDa protein, which is clearly present in PC-
3 and PC-3M-LN4 cells (data not shown). This protein was isolated
and sequenced using mass spectrometry. Peptide sequences
(Table 2) identified this protein as HSPA9B, a member of the
hsp70 family, also known as mortalin, PBP74, mthsp70 or MOT.
Using an anti-HSPA9B monoclonal antibody, we confirmed that
mortalin is expressed in both PC-3 and PC-3M-LN4 cell lines
(Figure 4A), regardless from the fact that CD9 overexpression had
contrasting effects on their viability (Table 1). Furthermore,
immunoprecipitation of cell lysates with an anti-CD9 antibody
resulted in co-precipitation of mortalin (Figure 4B). Converse
immunoprecipitation with anti-mortalin antibody revealed CD9 on
immunoblot (Figure 4C), confirming their interaction in prostate
cancer cells. Although not quantitative, we could not detect any
significant difference in the amount of CD9 immunoprecipitated
with the mortalin antibody in PC-3 and PC-3M-LN4 cells.
Colocalisation of mortalin and CD9 in prostate cancer cells
Earlier reports demonstrated that subcellular distribution of
mortalin differed significantly in various cancer cells and allowed
classification of cells into four senescence groups (Wadhwa et al,
1995). We compared the localisation of CD9 and mortalin by
immunofluorescent staining in PC-3 and PC-3M-LN4 cells. In PC-3
cells, mortalin expression follows a perinuclear pattern (Figure 5B)
whereas in PC-3M-LN4 cells, mortalin is seen as a gradient from
the nucleus to the cell membrane (Figure 5E). In contrast, CD9
expression pattern was the same (a weak diffuse-typed cytoplasm
with occasional cell membrane staining) in both cell lines (Figure
5A and D). Although these two proteins co-immunoprecipitated,
confocal microscopy analysis failed to show colocalisation of the
two proteins in these cells (Figure 5C and F). Since mortalin
expression has been implicated in cell senescence and immorta-
lisation (Kaul et al, 1998; Wadhwa et al, 2004), we determined if
mortalin distribution was affected in CD9-transfected PC-3 cells
undergoing mitotic catastrophe.
PC-3 cells were once again transfected with wild-type CD9 and
24 new PC-3CD9 clones were obtained. These cells were kept in
culture and observed until (for the third time) signs of mitotic
catastrophe became obvious. Double immunofluorescent staining
with both anti-CD9 and anti-mortalin mAbs was then performed.
Untransfected PC-3 and PC-3M-LN4 cells and PC-3M-LN4 cells
overexpressing CD9 (PC-3M-LN4CD9-40 clone without mitotic
catastrophe induction) were used as controls. Confocal micro-
scopic analysis clearly showed that CD9 and mortalin colocalised
in PC-3CD9 transfectants undergoing mitotic catastrophe
(Figure 5I). Under these conditions, mortalin expression was
switched from a perinuclear distribution (as in Figure 5B) to a
pancytoplasmic localisation (Figure 5H), where it colocalised with
CD9 (Figure 5I). These two proteins, although also expressed in the
other cells analysed, did not colocalise in the absence of mitotic
catastrophe (Figure 5C, F and L). Overexpression of CD9 in the
more invasive PC-3M-LN4CD9-40 cells did not result in coloca-
lisation of CD9 and mortalin (Figure 5L). Thus, CD9 and mortalin
colocalisation seems to happen only when cells are undergoing
mitotic catastrophe.
Table 2 Sequence of peptides derived from the 75-kDa CD9-
immunoprecipitated protein
Peptides Amino-acid location in mortalin
LYSPSQIGAFVLMK 160–173
MKETAENYLGHTAK 174–187
NAVITVPAYFNDSQR 188–202
VINEPTAAALAYGLDK 219–234
ETGVDLTKDNMALQR 293–307
AQFEGIVTDLIRR 349–361
VQQTVQDLFGR 395–405
LLGQFTLIGIPPAPR 499–513
LFEMAYK 647–653
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Figure 4 Analysis of mortalin expression in prostate cancer cells. (A)
Detection of mortalin in prostate cancer cells by Western immunoblot
using mortalin monoclonal antibody. Actin detection was performed to
confirm equal protein sample loading. (B) PC-3, PC-3M-LN4 and PC-3M-
LN4CD9-40 cells were lysed in 1% Brij 97, protein extracts were
immunoprecipitated with either cluster-of-differentiation antigen 9 (CD9)
mAb or IgG, separated on SDS-PAGE, transferred to nylon membrane and
revealed with mortalin mAb. Immunoprecipitation with non-specific IgG
(mouse) was performed for non-specific band detection. (C) PC-3 cells
were lysed in 1% Brij 97, protein extracts were immunoprecipitated with
mortalin mAb, separated on SDS-PAGE, transferred to nylon membrane
and revealed with CD9 mAb. Cell lysate from PC-3M-LN4 cells was loaded
as a control for CD9 detection.
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Mitotic catastrophe is the main form of cell death induced by
ionising radiation (Cohen-Jonathan et al, 1999) but can also be
induced, albeit at low percentage, by different classes of cytotoxic
agents such as etoposide (Lock and Stribinskiene, 1996), taxol
(Torres and Horwitz, 1998), cisplatin or bleomycin (Tounekti et al,
1993). Since such treatments are currently used with more or less
success against different types of cancer, there could be
tremendous benefits in identifying genes that can induce mitotic
catastrophe. By overexpressing CD9 in PC-3 cells, we demon-
strated that this tetraspanin plays an active role in this process.
Indeed, sustained overexpression of CD9 in these cells (maintained
in a third of transfected clones) resulted in mitotic catastrophe,
although at different times for different clones (Figure 2). Such
delay is also a characteristic of mitotic catastrophe induction
(Roninson et al, 2001), since cells first need to exit a growth arrest
state and resume cell division for mitotic catastrophe to occur.
Using converse co-immunoprecipitation, we confirmed that
mortalin is a new CD9 partner in prostate cancer cells. Mortalin is
a highly conserved member of the hsp70 family of proteins, which
was first identified by its presence in cytoplasmic fractions of
normal mouse fibroblasts and its absence in similar fractions from
immortal cells (Wadhwa et al, 1993a). Mortalin is predominantly
present in mitochondria, but also reported in endoplasmic
reticulum, cytoplasmic vesicles and cytosol (Ran et al, 2000).
Mortalin is ubiquitously expressed, and so far has been detected in
all mammalian cells analysed. This protein has been implicated in
stress response (Ornatsky et al, 1995), muscle activity (Ibi et al,
1996), mitochondrial biogenesis (Schneider and Hood, 2000),
control of cell proliferation (Kaul et al, 2000b), intracellular
trafficking (Mizukoshi et al, 2001), differentiation (Xu et al, 1999)
and tumorigenesis (Takahashi et al, 1994; Kaul et al, 1998;
Wadhwa et al, 2006). Expression level of mortalin is frequently
increased in tumours (Kaul et al, 2002; Dundas et al, 2005), where
it is believed to cause inactivation of tumour suppressor protein
TP53 (Wadhwa et al, 1998).
Immunofluorescence studies on mortalin localisation in more
than 50 cell lines demonstrated differences in its distribution in
normal and transformed human cells (Kaul et al, 2002). Indeed, in
a study of cell senescence (Pereira-Smith and Smith, 1988), 30
immortal human cell lines were assigned to four complementation
groups. Differences in pattern of mortalin distribution were later
on associated with these four complementation groups (Wadhwa
et al, 1995), highlighting mortalin involvement in senescence
mechanisms. These observations, combined with the differential
effects of CD9 overexpression in prostate cancer cells demon-
strated in this study, led us to hypothesise that mortalin
distribution in PC-3 and PC-3M-LN4 cells could also differ.
Immunofluorescent studies demonstrated that the pattern of
mortalin expression in PC-3 and PC-3M-LN4 cells was indeed
different and thus classify these two closely related cell lines in two
different senescence groups. PC-3 would thus belong to group C,
with a granular–juxtanuclear arch mortalin staining, while PC-
3M-LN4 cells, never showing such perinuclear staining, exhibited
instead a granular gradient of mortalin expression from the
CD9
PC-3
PC-3M-LN4
PC-3CD9wt
PC-3M-LN4CD9-40
Mortalin Merged
AB C
DE F
GH I
JKL
Figure 5 Immunofluorescence analysis of cluster-of-differentiation antigen 9 (CD9) and mortalin in prostate cancer cells. Confocal laser scanning
micrographs show staining for CD9 (red signals: A, D, G and J) and mortalin antigens (green signals: B, E, H and K). Overlap of signals in merged images
revealed colocalisation of CD9 and mortalin in cells undergoing mitotic catastrophe (yellow staining in panel I). No protein colocalisation is detected in the
other images (C, F and L).
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group B (Wadhwa et al, 1995).
Although mortalin is present in CD9 immunoprecipitates from
both PC-3 and PC-3M-LN4 cells, confocal analysis revealed that in
cells, CD9 and mortalin colocalisation occurred only during CD9-
induced mitotic catastrophe. These apparently contradictory
results can be explained if one supposes that the perinuclear
localisation of mortalin is essential to allow close contact between
CD9 and mortalin. When cells are lysed, mortalin compartmenta-
lisation is obviously released, allowing co-immunoprecipitation
with CD9, confirming their interaction. Such importance for
mortalin cellular localisation is also in agreement with the
involvement of this protein in the different senescence groups
(Wadhwa et al, 1995).
Our results also indicate that CD9 and mortalin interactions
differ between PC-3 and PC-3M-LN4 cell lines. Although we cannot
rule out that the strong interaction between CD9 and mortalin in
PC-3 cells (seen in colocalisation studies, Figure 5I) could be due
to a difference in the amount of proteins implicated in these
complexes, taken together, our results argue that a perinuclear
localisation of mortalin (as in PC-3 cells) is required for CD9-
induced mitotic catastrophe and CD9/mortalin colocalisation. It is
interesting to note that the importance of such differences in
mortalin localisation was also seen with the two isoforms (mot-1
and mot-2) of mouse mortalin. Indeed, overexpression of the
pancytoplasmic mot-1 protein is sufficient to induce cell
senescence in NIH 3T3 mouse fibroblasts (Wadhwa et al, 1993b),
while introduction of the mot-2 perinuclear mortalin induced their
malignant transformation Kaul et al (1998). Since mouse mot-1
and mot-2 isoforms differ only by two amino acids (Kaul et al,
2000a), it is tempting to speculate that in human, where there is
only one mortalin isoform, this dual mortalin function is insured
by the binding of mortalin to specific partners, such as CD9.
Perinuclar localisation of mortalin could thus not only define a
senescence group (Wadhwa et al, 1995), but also identify cells or
tumour types that will be sensitive to CD9 overexpression. If
confirmed, such properties could eventually lead to a more
targeted approach in cancer treatment.
The link between mortalin inactivation and cell senescence or
cell death is very well established. Indeed, a reduction of mortalin
expression using an RNA–helicase-coupled hybrid ribozyme
resulted in cell growth arrest of HT1080 human fibrosarcoma
cells (Wadhwa et al, 2003). Such reduction of mortalin was
accompanied by an increase in TP53 expression (Wadhwa et al,
2003), which could indicate that mortalin interferes with the TP53
protein. Moreover, reduction of mortalin level by antisense RNA is
sufficient to induce cell senescence, with the appearance of
enlarged cells (Wadhwa et al, 2004). Reduction of mortalin
expression with specific shRNA also resulted in growth arrest in
human U2OS osteocarcinoma cells (Kaul et al, 2006). Our results
will thus argue that the strong interaction and colocalisation of
mortalin and CD9 seen in PC-3 cells results in inactivation of
mortalin functions, which eventually lead to mitotic catastrophe.
This phenotype, however, is not strictly dependent on wild-type
TP53 functions, as PC-3 cells are not expressing this protein due to
a frame-shift mutation (Isaacs et al, 1991).
In conclusion, we demonstrated that overexpression of CD9 in
PC-3 cells creates appropriate conditions for CD9 and mortalin
protein interactions, apparently by affecting distribution and/or
expression of mortalin. Under such conditions, PC-3 cells undergo
mitotic catastrophe. The ability to initiate cell death in cancer cells
is very important to prevent unregulated cell growth. Our results
showed that CD9 interactions with mortalin are linked to cell death
through mitotic catastrophe in prostate cancer cells, showing the
importance of CD9 in tumour suppression. Nevertheless, the
mechanisms by which these two proteins can induce mitotic
catastrophe are not clear and will require further elucidation.
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